Image of two soldiers looking at a drone
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Artificial intelligence-based defense technology designer Droneshield Ltd (ASX:DRO) has seen its share price spike up more than 4% on news of a $13.5 million contract from a US government customer for its dismounted Counter-UxS (or C-UxS) systems.

The contract was for a repeat order of the C-UxS systems – which target multi-domain aerial, ground and maritime surface drones – with the product delivery and cash receipt both factored into for completion by the end of 2024.

Droneshield director of Business Development Tom Branstetter said the contract was evidence of client confidence in the company’s suite of drone defense products.

“DroneShield’s ability to rapidly deliver high-performance, lifesaving technology at this scale sets us apart in the counter-UAS industry, empowering our clients with cutting-edge solutions precisely when they need it,” he said.

At 10:49 AEDT, shares in Droneshield were trading at $1.40 – a rise of 4.89% since the market opened.

Join the discussion: See what HotCopper users are saying about Droneshield and be part of the conversations that move the markets.

DRO by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Financials lead index higher after Trump inauguration | January 21, 2025

The local index clawed back losses throughout the afternoon as investors reacted to Trump’s impending decisions…
The Market Online Video

‘Where there’s risk, there’s reward’: Stab on asset manager the year’s first Hot Stock tip

Wealth Within senior analyst Fil Tortevski and analyst Pedro Banales have named their first HotCopper Hot Stock tip of the year,
REIT concept

Trump is banning work-from-home for Federal workers. Could our REIT index see contagion upside?

To answer the question at the top of the article, any benefit for Australian REIT stocks posed by Trump’s decision to ban work-from-home
Image of clinical researcher making notes

‘Significant’ new milestone for Recce in clinical testing of skin infection gel

Recce Pharmaceuticals Ltd has seen its share price rise more than 1% as it completes dosing…